245 related articles for article (PubMed ID: 25036800)
1. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
Tagde A; Singh H; Kang MH; Reynolds CP
Blood Cancer J; 2014 Jul; 4(7):e229. PubMed ID: 25036800
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
3. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
Anderson CP; Tsai J; Chan W; Park CK; Tian L; Lui RM; Forman HJ; Reynolds CP
Eur J Cancer; 1997 Oct; 33(12):2016-9. PubMed ID: 9516845
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
5. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
Yang B; Keshelava N; Anderson CP; Reynolds CP
Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
[TBL] [Abstract][Full Text] [Related]
7. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells.
Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
Biochem Pharmacol; 1999 Aug; 58(4):655-64. PubMed ID: 10413303
[TBL] [Abstract][Full Text] [Related]
8. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
Anderson CP; Keshelava N; Satake N; Meek WH; Reynolds CP
Med Pediatr Oncol; 2000 Dec; 35(6):659-62. PubMed ID: 11107141
[TBL] [Abstract][Full Text] [Related]
9. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
Cancer Chemother Pharmacol; 1999; 44(2):111-6. PubMed ID: 10412944
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
Ongaro A; Pellati A; De Mattei M; De Terlizzi F; Rossi CR; Campana LG
Anticancer Drugs; 2015 Mar; 26(3):284-92. PubMed ID: 25514113
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells.
Lee HM; Kim DH; Lee HL; Cha B; Kang DH; Jeong YI
Arch Pharm Res; 2019 Nov; 42(11):990-999. PubMed ID: 31482490
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
Dorr RT; Liddil JD; Soble MJ
Invest New Drugs; 1986; 4(4):305-13. PubMed ID: 3583642
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
16. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
[TBL] [Abstract][Full Text] [Related]
17. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Wu XX; Ogawa O; Kakehi Y
Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
[TBL] [Abstract][Full Text] [Related]
19. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
20. Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalan.
Dorr RT
Biochem Biophys Res Commun; 1987 Apr; 144(1):47-52. PubMed ID: 3579919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
